Skip to content

bupropion therapy in multiple sclerosis patient

bupropion efficacy on sexual arousal and interest among female patient suffering multiple sclerosis

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20120302009188N2
Enrollment
60
Registered
2020-02-15
Start date
2019-10-21
Completion date
Unknown
Last updated
2020-02-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

multiple sclerosis. Multiple sclerosis

Interventions

Intervention 1: Intervention group:bupropion tablets are formed in 2 dosage 75 and 150 mg.in this study therapy is started with 75 mg daily and according to patient response to the drug the dosage wil

Sponsors

Esfahan University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 50 Years

Inclusion criteria

Inclusion criteria: ability to read and write age between 18-50 year old use of a contraception method and no planning for pregnancy being in sexual relation for at least 6 months and do not think about divorce or separation and have sexual intercourse with her partner routinely diagnosis of sexual arousal and interest disorder according to FSFI

Exclusion criteria

Exclusion criteria: having a partner with sexual disorder suffering from an acute psychiatric disorder (with the exception of depression) having sexual pain disorder(disparunia or vaginismus),gender identity disorder, paraphilia menopause having primary or secondary infertility history of convulsion or head injury substance or alcohol abuse in previous year taking psychiatric drug or any medication which affect sexual function receiving a psychotherapy simultaneously

Design outcomes

Primary

MeasureTime frame
Sexual function rate in female sexual function index questionnaire. Timepoint: measurement of female sexual function index at the beginning of the study(before intervention) and 4,8 weeks after taking Bupropion. Method of measurement: female sexual function index questionnaire.

Secondary

MeasureTime frame
Fatigue severity. Timepoint: measurement of fatigue severity at the beginning of the study and 4,8 weeks after taking Bupropion. Method of measurement: fatigue severity scale.;Beck depression scale. Timepoint: measurement of depression at the beginning of the study and 4,8 weeks after taking Bupropion. Method of measurement: beck depression inventory.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMajid barekatain

Esfahan University of Medical Sciences

barekatain@med.mui.ac.ir+98 31 3222 2475

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026